Oncology

Oncology Review CME / CPD 

Full Course:  20 AMA PRA Category 1 Credits for CME / CEU / CPD

Short Course:  10 AMA PRA Category 1 Credits for CME / CEU / CPD

Course(s) are appropriate for:   Family Practitioners, Pediatricians, Internists, General Practitioners, Nurses, Nurse Practitioners, Physician Assistants (PA-C's)

Series 41 (ONC41) Topics Include:  Re-irradiation with IMRT, Lymph Node Transplantation for Lymphedema, New Therapies for AML, Treatment of Renal Cell Carcinoma, Subtypes of Sarcoma, and more.

To view topic outline of the full or short course, select the Course Type (Full or Short) below:

Full Course:
ONC41
Full Course Price:
$580
Short Course:
ONC41A, ONC41B
Short Course Price:
$485
Format:
Available in Audio format.

Course Topics

Highlights from the 2018 Multidisciplinary Head and Neck Cancer Update: the 6th Annual Symposium, Part 2

Summarize the efficacy of cetuximab-based chemoradiation therapy for patients with oropharyngeal cancer; Cite common toxicities associated with cetuximab; Identify factors associated with good outcomes after re-irradiation with intensity-modulated radiation therapy (IMRT) for recurrent or second primary head and neck cancer; Select optimal dose and fractionation for re-irradiation with IMRT, stereotactic body radiation therapy, and proton therapy in head and neck cancer; Prescribe re-irradiation therapy for head and neck cancer based on risk factors and physical fitness of the patient.

QUALIFIES FOR CLINICAL PHARMACOLOGY

Highlights from the Scripps Cancer Center's 38th Annual Conference: Clinical Hematology and Oncology 2018

Select from sublobar resection, lobectomy, or radiation therapy for non-small cell lung cancer on the basis of tumor size and patient comorbidities; Identify patients with lung cancer who should receive adjuvant radiation therapy on the basis of disease stage; Evaluate the benefits of adjuvant chemotherapy, targeted therapy, and immunotherapy for lung cancer; Summarize the efficacy and toxicity of adjuvant therapies for melanoma; Recognize the potential benefits of neoadjuvant therapy for melanoma.

QUALIFIES FOR CLINICAL PHARMACOLOGY

Highlights from the Chicago Breast Symposium and 7th World Symposium on Lymphedema Surgery

Use anatomic considerations to optimize outcomes from lymph node transfer for lymphedema; Describe the benefits of performing the Lymphatic Microsurgical Preventing Healing Approach (LYMPHA) procedure before breast cancer surgery; Discuss techniques for optimizing outcomes of lymphovenous bypass and lymph node transplantation for lymphedema; Explain how axillary reverse mapping can be used to reduce risk for lymphedema after sentinel lymph node biopsy or complete axillary node dissection; Estimate the efficacy of the simplified LYMPHA procedure and reapproximation for reducing risk for lymphedema after surgery for breast cancer.

History of Pediatric Leukemia: Diagnosis and Treatment

Summarize epidemiology, clinical presentation, and predisposing conditions associated with ALL in pediatric patients; Predict the risk for relapse of pediatric ALL based on patient age, white blood cell count, and minimal residual disease status after induction therapy; Discuss cytogenetic features of pediatric ALL and their association with disease prognosis; Describe how chimeric antigen receptor-T cell therapy may be effective for treating patients with ALL who relapse after chemotherapy and stem cell transplant; Manage the long-term effects of chemotherapy, radiation therapy, surgery, and stem cell transplant in survivors of pediatric cancer.

QUALIFIES FOR CLINICAL PHARMACOLOGY

Update on Acute Myeloid Leukemia

Identify the incidence of and level of risk associated with clinically actionable mutations in AML; Describe clinical characteristics associated with FLT3-and IDH-mutated AML; Discuss how karyotype and previous exposure to hypomethylating agents affect response to new therapies for AML; Cite common adverse events associated with new therapies for AML; Explain the relationship between minimal residual disease status and survival outcomes in AML.

Update on Prostate Cancer

Optimize the use of cryotherapy to treat prostate cancer; Reduce the risk for complications of cryotherapy in patients with prostate cancer; Assess the findings of studies comparing radical prostatectomy with observation, watchful waiting, or active monitoring; Evaluate the safety and efficacy of systemic therapies for prostate cancer based on recent studies; Recognize the biologic characteristics of prostate cancer and their association with the development of metastases and response to therapies.

QUALIFIES FOR CLINICAL PHARMACOLOGY

Biomarkers for Immunotherapy/Update on Renal Cancer

Predict response to immunotherapy using level of expression of programmed death ligand 1 (PD-L1); Recognize the potential roles of immune cells, microsatellite instability, and tumor mutation burden in predicting response to immunotherapy; Identify tumor types with potential for high microsatellite instability or mutation burden; Elaborate on the efficacy of targeted therapies, immunotherapies, and combination therapies in the treatment of renal cell carcinoma; Select a treatment regimen for renal cell carcinoma based on the prognosis of the patient, resectability of the tumor, and presence of metastases.

Highlights from the Chicago Breast Symposium and 7th World Symposium on Lymphedema Surgery

Summarize outcomes of nipple-sparing mastectomy in both risk-reduction and therapeutic settings; Cite absolute and relative contraindications for nipple-sparing mastectomy; Describe procedures for combined breast reconstruction and vascularized lymph node transfer for patients with postmastectomy lymphedema; Select patients with lymphedema who are likely to benefit from combining liposuction with lymphovenous anastomosis or vascularized lymph node transfer; Identify patients at high risk for ischemic complications who would likely benefit from nipple delay before nipple-sparing mastectomy.

Update on Abdominal Sarcomas

Recognize differences in locoregional recurrence, distant metastasis, and survival according to histologic subtype of retroperitoneal sarcoma; Select appropriate strategies for primary surgery of retroperitoneal sarcoma on the basis of tumor histology and anatomic location; Explain the role of radiation therapy in the treatment of retroperitoneal sarcoma; Evaluate patients with recurrent retroperitoneal sarcoma to determine surgical candidacy; Summarize ways to improve clinical trial design to evaluate responses to therapy in patients with different subtypes of sarcoma.

QUALIFIES FOR CLINICAL PHARMACOLOGY

Sarcomas and Metastasis of the Spine/ Pediatric Musculoskeletal Oncology

Use classification systems to determine optimal strategies for surgical management or palliative care of primary and metastatic spinal sarcomas; Develop multidisciplinary approaches for management of primary and metastatic spinal sarcomas; Evaluate neurologic function, oncologic status, mechanical status, and systemic disease to determine optimal management for patients with metastatic spinal sarcomas; Compare rates of local disease, distant metastasis, and overall survival between pediatric and adult patients with sarcoma; Recognize differences in treatment protocols and side effects between pediatric and adult patients with sarcoma.

QUALIFIES FOR CLINICAL PHARMACOLOGY

Additional Information

Additional Continuing Medical Education options available:

Other courses of interest may include:  SurgeryFamily PracticeInternal MedicineObesity and Nutrition.

If you have taken the current Oncology CME / CPD Review listed above or if you are seeking additional credits, please visit: Medical Courses Coming Soon There you will find abbreviated listings of additional courses available related to this specialty and courses that are soon to be released.

For over 30 years, ASI has provided Continuing Medical Education, CME & CEU and Continuing Professional Development Education (CPD) for physicians and allied professionals in Oncology plus over 40 other specialties and subspecialties.  Lectures are recorded annually at the top seminars and conferences to provide the most current medical education to our clients.

Specialty

Interactive Courses